

February 2020

To whom it may concern:

The complete range of Intersurgical breathing filters has been validated against the passage of a variety of bacterial and viral species of varying particle sizes.

The Clear-Guard Midi filtration device (code 1644000) has been independently validated against the passage of *Bacillus subtilis* (1.0µm x 0.7µm) and φ174 bacteriophage (0.027µm) to represent the bacterial and viral challenge it may face in the clinical environment. These tests show the filter to be >99.9% efficient against these challenge organisms.

The challenge presented in the viral test protocol (φ174 bacteriophage, 0.027 µm) will be at least as severe as that posed by the Coronavirus (COVID-19) which originated in Wuhan PRC (0.05 - 0.1µm).

As such, it can be concluded that the 1644xxx range of products will provide at least the same level of quoted efficiency (>99.9%) as reported in the independent microbiology tests when challenged with Coronavirus. Copies of these test protocols are available upon request.



Ivan Seniut  
Group Quality and Regulatory Affairs Director  
Duly authorised for and on behalf of Intersurgical Ltd